Skip to main content

Jesse David Troy

Associate Professor of Biostatistics & Bioinformatics
Biostatistics & Bioinformatics, Division of Biostatistics
Box 2721, Durham, NC 27710
2424 Erwin Rd., Box 2721, Durham, NC 27710

Available to Mentor


  • Affiliate
  • Fellow
  • Masters
  • PhD
  • Resident
  • Undergraduate

Advising & Mentoring


Completed Projects

Master of Biostatistics Program

  • Noah Graham (2020) (Advisor): Accounting for Selection Bias due to Missing Data in Evaluation of the Impact of Oncotype DX Recurrence Scoring on Adjuvant Chemotherapy Receipt among Breast Cancer Patients in the National Cancer Database.
  • Allison Reagan (2020) (Advisor): The Interplay Between Age, Comorbidity, and Timing of Androgen Deprivation Therapy on Survival After Recurrent Prostate Cancer
  • Marissa Trotta (2021) (Advisor): Using Multiple Imputation and Pattern Mixture Models to Evaluate Assumptions About Missing Data in the ACCeNT Trial
  • Ryan Milligan (2021) (Advisor): Analyzing the Impact of Missing Data from a Clinical Trial of Stem Cell Therapy for Cerebral Palsy Patients
  • Yiyang Zhang (2022) (Committee member): Very Low Birth Weight (VLBW) Preterm infant Health Outcomes with Bundle Care in the Neonatal Intensive Care Unit
  • Yifeng Tang (2022) (Committee member): Investigating the differences between the Family-Based association test and General Linear Mixed Model for related data
  • Chuxuan Sun (2022) (Committee member): Identifying the risk of the Second Primary Malignancies Among Primary Malignant Breast Cancer Survivors in the United States with Grouped-Lasso Cox Model in SEER
  • Si Zhou (2022) (Committee member): Assessing the adequacy of lymph node yield (LNY) for head and neck cancer
  • Morgan Paul (2023) (Advisor): Outcomes Associated with Surgery for Contralateral Axillary Metastasis Using Bayesian Methods
  • Liz Nichols (2023) (Committee member): Comparison of Methods for Assessing Treatment Effect Estimates in a Pragmatic Cluster Pre/Post Implementation Trial
  • Ashley Weeks (2023) (Committee member): Pertuzumab + Trastuzumab in Patients with Malignant Neoplasm of Gallbladder and Bile Ducts with ERBB2 or ERBB3 Alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
  • Xianxin Zhu (2023) (Committee member): Olaparib in Patient with Metastatic Breast Cancer with mutational BRCA1/BRCA2 germline by The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
  • Nick Bachelder (2024) (Committee member): An Ecologic Study of Socioeconomic Risk for Different Types of Cancer Mortality
  • Will Powell (2024) (Committee member): Analysis of GLP-1 Use on Weight Change and Mobility outcomes in individuals with Neurological conditions
  • Molly Ehrig (2024) (Committee member): An Investigation of Missing Data Approaches in the Analysis of Longitudinal Health Data


Clinical Research Training Program

  • Julia Messina, MD (2020) (Committee member): Genomic Characterization of Enterococcal Bloodstream Isolates in Hematologic Malignancies
  • Emily Eichenberger, MD  (2022) (Committee member): Gram-negative bacteremia in solid organ transplant recipients: clinical characteristics and outcomes as compared to non-transplant recipients
  • Diana Ximena Nichols-Vinueza, MD  (2022) (Committee member): Assessment of Bone Density in Children with Food Allergies
  • Anahita Mostaghim, MD (2024) (Committee member): Risk factors for ICU admission and mortality in patients who develop gram negative bacteremia in the first 100 days after hematopoietic cell transplant
  • Ahmad Mourad, MD (2024) (Committee member): Clinical outcomes in patients with Piperacillin-tazobactam non-susceptible but Ceftriaxone susceptible Enterobacteriaceae spp. bacteremia
  • Urania Dagalakis, MD (2024) (Committee member): Longitudinal follow-up and outcomes of Pediatric and Adult Patients with SDH-deficient GIST
  • Sarah Peters, MD (2025) (Committee member): Investigating a Biopsychosocial Model of Fatigue in Patients with Neuroendocrine Neoplasms
  • Elias Chuki, MD (2024) (Committee member): Progression-Free Survival in Familial Non-medullary Thyroid Cancer and Sporadic Differentiated Thyroid Cancer Patients